Drug intelligence / Profile preview

ESR-114

Development stage: Phase 2
Lead developer: Escalier Biosciences
Modality: Small Molecules
Administration: Topical

Overview

ESR-114 is a selective, potent small molecule inhibitor of retinoic acid-related orphan nuclear receptor gamma t (RORγt), also known as nuclear receptor subfamily 1 group F member 3. It is being developed as a topical gel formulation designed to target its pharmacological activity to the skin with minimal systemic absorption. The mechanism of action involves antagonism of RORγt, which reduces production of the inflammatory cytokine IL-17—a key driver in psoriasis and other autoimmune disorders. The drug is primarily being investigated for the treatment of plaque psoriasis, with clinical trials reaching Phase 1/2a status in patients with mild-to-moderate disease[1][2][3][4].

Other names: ESR 114ESR114ESR-114

Targets

RORγt

Beyond the preview

Go deeper on ESR-114.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ESR-114.

Explore the full profile